Roberts Labs
Executive Summary
Firm announced a cooperative research agreement with U.K.-based Johnson Matthey under which Roberts will receive worldwide rights to all radiosensitizer drugs synthesized by Johnson Matthey for an undisclosed amount of cash. Compounds include organometallic hypoxic tumor cell radiosensitizers, oxic tumor cell radiosensitizers and targeted radiosensitizers.